Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03LMH
|
|||
| Former ID |
DNC008981
|
|||
| Drug Name |
N-Phenylethyl-ETAV
|
|||
| Synonyms |
N-Phenylethyl-ETAV; CHEMBL494895
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H38N4O8
|
|||
| Canonical SMILES |
CC(C)C(C(=O)O)NC(=O)C(C)NC(=O)C(C(C)O)NC(=O)C(CCC(=O)O)NCCC1=CC=CC=C1
|
|||
| InChI |
1S/C25H38N4O8/c1-14(2)20(25(36)37)28-22(33)15(3)27-24(35)21(16(4)30)29-23(34)18(10-11-19(31)32)26-13-12-17-8-6-5-7-9-17/h5-9,14-16,18,20-21,26,30H,10-13H2,1-4H3,(H,27,35)(H,28,33)(H,29,34)(H,31,32)(H,36,37)/t15-,16?,18-,20-,21-/m0/s1
|
|||
| InChIKey |
DJKUAJMLBSOLFF-GDEPEFMTSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Presynaptic density protein 95 (DLG4) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Hippo signaling pathway | |||
| Glutamatergic synapse | ||||
| Huntington's disease | ||||
| Cocaine addiction | ||||
| Panther Pathway | Huntington disease | |||
| Pathway Interaction Database | ErbB4 signaling events | |||
| Reactome | Trafficking of AMPA receptors | |||
| Unblocking of NMDA receptor, glutamate binding and activation | ||||
| CREB phosphorylation through the activation of CaMKII | ||||
| Ras activation uopn Ca2+ infux through NMDA receptor | ||||
| RHO GTPases activate CIT | ||||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| L1CAM interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.